Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Novo Nordisk A/S
- Study ID
- NCT07817251
- Phase
- PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- CagriSema — DRUGCagriSema will be administered s.c. once weekly.
Study Details
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.
Key Dates
- First listed
- Sep 14, 2026
- Start date
- Sep 16, 2026
- Status verified
- Sep 2026
- Primary completion
- Jun 9, 2027
- Completion
- Jul 21, 2027
Study Design
- Enrollment
- 210 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: CagriSema dose 1Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.
- Experimental: CagriSema dose 2Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 2, followed by dose 1.
- Experimental: CagriSema dose 3Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.
Primary Outcome Measure
Number of treatment emergent adverse events (TEAEs) [ Time Frame: From baseline (Week 0) to end of treatment (Week 16) ]
Central Contacts
- Novo Nordisk(+1) 866-867-7178
Locations (40)
Find similar trials in Gilbert, AZ
By condition
By specialty
Related Studies
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
- Use of CGM in Kidney Transplant RecipientsRecruiting · University of California, Davis · Sacramento, California
- DETERMINE: Detemir vs NPHPHASE2 · Recruiting · University of California, Los Angeles · Los Angeles, California
- Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin ResistanceRecruiting · Stanford University · Stanford, California